Voyager Therapeutics to Appoint Omar Khwaja as Chief Medical Officer
January 15, 2019 at 07:03 am
Share
Voyager Therapeutics, Inc. announced the appointment of Omar Khwaja, M.D., Ph.D., as chief medical officer. Dr. Khwaja's background includes extensive research, translational, and clinical therapeutic development experience in neuroscience, neurogenetics and rare disease in both industry and academic roles. Dr. Khwaja is joining Voyager from F. Hoffmann-La Roche AG (Roche) where he most recently served as Global Head of Neuroscience Translational Medicine and Global Head of Rare Diseases. Before joining Roche, Dr. Khwaja was Director of the Clinical Neurogenetics Program at Boston Children's Hospital and on the faculty of Harvard Medical School.
Voyager Therapeutics, Inc. is a biotechnology company focused on advancing neurogenetic medicines. The Companyâs pipeline includes programs for Alzheimerâs disease, amyotrophic lateral sclerosis (ALS), Parkinsonâs disease, and multiple other diseases of the central nervous system. Many of its programs are derived from its TRACER AAV capsid discovery platform, which is used to generate novel capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Its pipeline of programs, all of which are in preclinical development, include Anti-Tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy Program, Tau Silencing Gene Therapy Program, Vectorized Anti-Amyloid Antibody Early Research Program, Friedreichâs Ataxia Program: VY-FXN01, GBA1 Gene Replacement Program, HD Program, and others. VY-TAU01 is for the treatment of Alzheimerâs disease. SOD1 Silencing Gene Therapy Program is for the treatment of ALS.